MaxCyte (NASDAQ:MXCT – Get Rating) and Absci (NASDAQ:ABSI – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings.
Analyst Recommendations
This is a breakdown of recent ratings for MaxCyte and Absci, as provided by MarketBeat.
Get
MaxCyte alerts:
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
| MaxCyte | 0 | 0 | 1 | 0 | 3.00 |
| Absci | 2 | 0 | 5 | 0 | 2.43 |
MaxCyte presently has a consensus price target of $11.00, suggesting a potential upside of 85.50%. Absci has a consensus price target of $14.00, suggesting a potential upside of 250.00%. Given Absci's higher probable upside, analysts clearly believe Absci is more favorable than MaxCyte.
Volatility and Risk
MaxCyte has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. Comparatively, Absci has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500.
Institutional & Insider Ownership
66.4% of MaxCyte shares are owned by institutional investors. Comparatively, 45.4% of Absci shares are owned by institutional investors. 5.1% of MaxCyte shares are owned by insiders. Comparatively, 19.4% of Absci shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares MaxCyte and Absci's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
| MaxCyte | -47.92% | -7.60% | -6.96% |
| Absci | -2,223.07% | -29.31% | -25.26% |
Earnings and Valuation
This table compares MaxCyte and Absci's top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
| MaxCyte | $33.89 million | 17.82 | -$19.08 million | ($0.20) | -29.65 |
| Absci | $4.78 million | 77.69 | -$100.96 million | ($1.26) | -3.17 |
MaxCyte has higher revenue and earnings than Absci. MaxCyte is trading at a lower price-to-earnings ratio than Absci, indicating that it is currently the more affordable of the two stocks.
Summary
MaxCyte beats Absci on 9 of the 14 factors compared between the two stocks.
About MaxCyte
(Get Rating)
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
About Absci
(Get Rating)
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
